Form 4: Janux CBO Sells Shares for Tax Obligations

Janux Therapeutics' Chief Business Officer, Andrew Hollman Meyer, sold 1,879 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Andrew Hollman Meyer, Chief Business Officer of Janux Therapeutics, Inc. (JANX), reported a transaction on January 2, 2026.
• The transaction involved the disposition of 1,879 shares of Janux Therapeutics Common Stock.
• The shares were sold at a price of $13.73 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Andrew Hollman Meyer beneficially owns 83,095 shares of Common Stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a routine, non-discretionary sale of shares to cover tax obligations upon RSU vesting, rather than a discretionary sale indicating a change in management's confidence or outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction, common across all industries, where executives sell a portion of their vested equity to cover tax liabilities. It does not reflect a discretionary sale based on a change in outlook for Janux Therapeutics or the broader biotechnology sector.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the company's fundamentals or management's confidence.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale by an insider to cover tax withholding obligations upon the vesting of restricted stock units. This type of transaction, especially when executed under a Rule 10b5-1 plan, does not provide new material information about the company's operational performance, strategic direction, or the insider's confidence in the company's future. Therefore, it does not warrant a change in investment recommendation, and a 'hold' stance is maintained based on existing fundamental analysis.

Keywords

Janux Therapeutics, JANX, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Chief Business Officer